This observation was confirmed in primary SDH-deficient GIST (patient #1) cells, which showed that cells cultured in medium with 1% FBS are more sensitive to olverembatinib treatment than those cultured with 3% or 10% FBS (Fig. 4c). The gene discussed is SDHB; the disease is gastrointestinal stromal tumor.